Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
1.
Nat Med ; 4(5): 581-7, 1998 May.
Artículo en Inglés | MEDLINE | ID: mdl-9585232

RESUMEN

In situ killing of tumor cells using suicide gene transfer to generate death by a non-apoptotic pathway was associated with high immunogenicity and induction of heat shock protein (hsp) expression. In contrast, a syngeneic colorectal tumor line, CMT93, killed predominantly by apoptosis, showed low levels of hsp expression and less immunogenicity. When apoptosis was inhibited in CMT93 cells by overexpression of bcl-2, hsp was also induced. Furthermore, when cDNA encoding hsp70 was stably transfected into B16 and CMT93 cells, its expression significantly enhanced the immunogenicity of both tumors. Increased levels of hsp, induced by non-apoptotic cell killing, may provide an immunostimulatory signal in vivo which helps break tolerance to tumor antigens. These findings have important implications for the development of novel anti-cancer therapies aimed at promoting patients' immune responses to their own tumors.


Asunto(s)
Antígenos de Neoplasias/inmunología , Muerte Celular , Neoplasias Colorrectales/inmunología , Proteínas HSP70 de Choque Térmico/biosíntesis , Melanoma Experimental/inmunología , Animales , Antivirales/farmacología , Apoptosis , Ganciclovir/farmacología , Ratones , Neoplasias Experimentales/inmunología , Proteínas Proto-Oncogénicas c-bcl-2 , Simplexvirus/enzimología , Timidina Quinasa
2.
Clin Transl Oncol ; 21(3): 363-372, 2019 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-30094792

RESUMEN

BACKGROUND: Vaccination of cancer patients with p53-expressing modified vaccinia Ankara virus (p53MVA) has shown in our previous studies to activate p53-reactive T cells in peripheral blood but without immediate clinical benefit. We hypothesized that the immunological responses to p53MVA vaccine may require additional immune checkpoint blockade to achieve clinically beneficial levels. We therefore conducted a phase I trial evaluating the combination of p53MVA and pembrolizumab (anti-PD-1) in patients with advanced solid tumors. PATIENTS AND METHODS: Eleven patients with advanced breast, pancreatic, hepatocellular, or head and neck cancer received up to 3 triweekly vaccines in combination with pembrolizumab given concurrently and thereafter, alone at 3-week intervals until disease progression. The patients were assessed for toxicity and clinical response. Correlative studies analyzed p53-reactive T cells and profile of immune function gene expression. RESULTS: We observed clinical responses in 3/11 patients who remained with stable disease for 30, 32, and 49 weeks. Two of these patients showed increased frequencies and persistence of p53-reactive CD8+ T cells and elevation of expression of multiple immune response genes. Borderline or undetectable p53-specific T cell responses in 7/11 patients were related to no immediate clinical benefit. The first study patient had a grade 5 fatal myocarditis. After the study was amended for enhanced cardiac monitoring, no additional cardiac toxicities were noted. CONCLUSION: We have shown that the combination of p53MVA vaccine with pembrolizumab is feasible, safe, and may offer clinical benefit in select group of patients that should be identified through further studies.


Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Antineoplásicos Inmunológicos/uso terapéutico , Vacunas contra el Cáncer/uso terapéutico , Terapia Combinada/métodos , Neoplasias/terapia , Adulto , Anciano , Linfocitos T CD8-positivos/inmunología , Vacunas contra el Cáncer/inmunología , Femenino , Vectores Genéticos , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/inmunología , Proteína p53 Supresora de Tumor/administración & dosificación , Proteína p53 Supresora de Tumor/inmunología
3.
Brain Lang ; 37(1): 90-121, 1989 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-2752277

RESUMEN

A total of 178 reading disabled children were randomly assigned to one of three treatment conditions providing training in word recognition and decoding skills (DS), oral and written language (OWLS), or classroom survival skills (CSS. an alternative treatment control). Pre- and post-treatment comparisons on an array of standardized and experimental measures indicated that the two experimental treatments (DS, OWLS) resulted in improvement on selected tests significantly greater than that resulting from a third treatment intervention which controlled for treatment time and individual attention (CSS). Effects specific to each experimental treatment were identified, as well as some generalized treatment advantages shared by both experimental groups at post-test. These results indicate that some of the deficits associated with developmental dyslexia are amenable to treatment. Greater generalization of treatment effects was observed following the DS than the OWLS treatment. While DS-instructed children exhibited better word recognition skills, however, their knowledge of grapheme-phoneme correspondence rules was not improved. Several OWLS-specific effects observed on experimental reading and language measures were not replicated on standardized tests which purport to measure the same skills. These results are discussed with respect to (i) possible mechanisms by which disabled readers may acquire word recognition skills, (ii) their failure to acquire and use grapheme-phoneme correspondence rules, and (iii) a possible reduced tendency in the present population to generalize newly acquired specific knowledge to related knowledge domains.


Asunto(s)
Dislexia/rehabilitación , Educación Compensatoria/métodos , Logro , Adolescente , Niño , Dislexia/psicología , Femenino , Estudios de Seguimiento , Humanos , Trastornos del Desarrollo del Lenguaje/rehabilitación , Masculino , Fonética , Semántica , Aprendizaje Verbal , Escritura
4.
Br J Dermatol ; 129(6): 718-22, 1993 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8286258

RESUMEN

We report two cases of superficial granulomatous pyoderma (SGP). Unlike classical pyoderma gangrenosum this variant is characterized by a benign course, superficial ulceration and a granulomatous infiltrate. Although our cases share the typical features of SGP, they are noteworthy in that one had the disease for 18 years, and the other had concomitant sarcoidosis.


Asunto(s)
Piodermia Gangrenosa/patología , Piel/patología , Enfermedad Crónica , Femenino , Humanos , Pierna , Persona de Mediana Edad , Piodermia Gangrenosa/complicaciones , Sarcoidosis/complicaciones , Úlcera Cutánea/patología , Tórax
5.
Br J Dermatol ; 115(2): 167-76, 1986 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-3741782

RESUMEN

A survey of 500 patients hospitalized in non-dermatology wards and referred for dermatological opinion is reported. In approximately 50%, the skin lesions were related to the presenting illness; in 36.6% of these patients the skin condition contributed substantially to the diagnosis of the systemic disease. This study emphasizes the considerable interface between cutaneous and systemic disease and the need for close co-operation between medical and dermatology departments. The implications for postgraduate education are highlighted, since such patients are infrequently seen in a dermatology out-patient setting.


Asunto(s)
Derivación y Consulta , Enfermedades de la Piel/diagnóstico , Anciano , Femenino , Hospitales Generales , Humanos , Masculino , Enfermedades de la Piel/etiología , Sudáfrica
6.
Br J Dermatol ; 132(3): 468-71, 1995 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-7718469

RESUMEN

We report a case of staphylococcal scalded skin syndrome in a 77-year-old man with an infected surgical wound. The patient was immunocompetent and had only mildly impaired renal function. The pathogenic and aetiological factors of the condition are discussed.


Asunto(s)
Síndrome Estafilocócico de la Piel Escaldada/patología , Anciano , Exfoliatinas/análisis , Humanos , Inmunocompetencia , Masculino , Síndrome Estafilocócico de la Piel Escaldada/inmunología
7.
Br J Dermatol ; 143(3): 595-7, 2000 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-10971335

RESUMEN

We report three patients newly diagnosed as having xeroderma pigmentosum (XP). Previous photobiological studies have implicated ultraviolet (UV) B as the activating waveband in XP, causing a delayed and prolonged erythemal response. This characteristic reaction pattern has been used as a quick screening test in patients suspected of having XP, while awaiting confirmatory DNA repair studies. Two of our patients showed no abnormal erythemal responses, and one showed severe photosensitivity from 330 to 400 nm but normal UVB responses, with a peak erythema at 24 h. We conclude that the erythemal responses in XP are highly variable and cannot be considered as a reliable screening test in the diagnosis of XP.


Asunto(s)
Eritema/etiología , Rayos Ultravioleta/efectos adversos , Xerodermia Pigmentosa/diagnóstico , Niño , Preescolar , Pruebas Genéticas , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Xerodermia Pigmentosa/genética
8.
Br J Dermatol ; 120(2): 229-38, 1989 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-2923796

RESUMEN

A survey was conducted to investigate the relationship between exogenous ochronosis and the use of skin lightening preparations amongst black individuals attending general outpatient departments in two South African hospitals. In the sample, 15% of males and 42% of females were found to have exogenous ochronosis. The prevalence amongst users of skin lighteners was 69%. The main demographic associations with ochronosis were an inverse relationship to education, and predominance of the female sex. Clinical and behavioural aspects were also recorded. Even products limited to 2% hydroquinone or less, and combined with a sunscreen, were found to cause ochronosis.


Asunto(s)
Negro o Afroamericano , Cosméticos/efectos adversos , Ocronosis/epidemiología , Adolescente , Adulto , Anciano , Población Negra , Femenino , Humanos , Hidroquinonas/efectos adversos , Masculino , Persona de Mediana Edad , Ocronosis/inducido químicamente , Sudáfrica
9.
J Immunol ; 163(3): 1398-408, 1999 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-10415040

RESUMEN

Previously, we reported that killing tumor cells in vivo with the HSV thymidine kinase/ganciclovir system generates potent antitumor immunity, determined in part by the mechanism by which the cells die and by the levels of inducible heat shock protein (hsp) expression induced during the process of cell death. Here, we show that induction of hsp70 expression induces an infiltrate of T cells, macrophages, and predominantly dendritic cells (DCs) into the tumors as well as an intratumoral profile of Th1 cytokine expression (IFN-gamma, TNF-alpha, and IL-12) and enhances immunogenicity via a T cell-mediated mechanism. In addition, the protection conferred by hsp70 is both tumor and cell specific. We also demonstrate that hsp70 targets immature APC to make them significantly more able to capture Ags. This is likely to optimize cross-priming of the infiltrating APC with tumor Ags, which are simultaneously being released by the dying cells. In addition, using an Myc epitope-tagged hsp70 expression vector, we present evidence that hsp70 released from dying tumor cells is taken up directly into DCs and may, therefore, be involved in direct chaperoning of Ags into DCs. Taken together, our data suggest that hsp70 induction serves to signal the immune system of the presence of an immunologically relevant (dangerous) situation against which an immune reaction should be raised.


Asunto(s)
Citocinas/biosíntesis , Citotoxicidad Inmunológica/inmunología , Células Dendríticas/inmunología , Células Dendríticas/metabolismo , Proteínas HSP70 de Choque Térmico/inmunología , Proteínas HSP70 de Choque Térmico/metabolismo , Células Madre Hematopoyéticas/metabolismo , Células TH1/metabolismo , Animales , Diferenciación Celular/inmunología , Fraccionamiento Celular , Movimiento Celular/inmunología , Células Dendríticas/citología , Proteínas HSP70 de Choque Térmico/biosíntesis , Células Madre Hematopoyéticas/inmunología , Antígenos de Histocompatibilidad Clase I/metabolismo , Inmunofenotipificación , Melanoma Experimental/inmunología , Melanoma Experimental/metabolismo , Melanoma Experimental/patología , Ratones , Ratones Endogámicos C57BL , Ratones Desnudos , Células TH1/inmunología , Escape del Tumor/inmunología
10.
Hum Mol Genet ; 12(11): 1241-52, 2003 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-12761039

RESUMEN

Germline mutations of the fumarate hydratase (FH, fumarase) gene are found in the recessive FH deficiency syndrome and in dominantly inherited susceptibility to multiple cutaneous and uterine leiomyomatosis (MCUL). We have previously reported a number of germline FH mutations from MCUL patients. In this study, we report additional FH mutations in MCUL and FH deficiency patients. Mutations can readily be found in about 75% of MCUL cases and most cases of FH deficiency. Some of the more common FH mutations are probably derived from founding individuals. Protein-truncating FH mutations are functionally null alleles. Disease-associated missense FH changes map to highly conserved residues, mostly in or around the enzyme's active site or activation site; we predict that these mutations severely compromise enzyme function. The mutation spectra in FH deficiency and MCUL are similar, although in the latter mutations tend to occur earlier in the gene and, perhaps, are more likely to result in a truncated or absent protein. We have found that not all mutation-carrier parents of FH deficiency children have a strong predisposition to leiomyomata. We have confirmed that renal carcinoma is sometimes part of MCUL, as part of the variant hereditary leiomyomatosis and renal cancer (HLRCC) syndrome, and have shown that these cancers may have either type II papillary or collecting duct morphology. We have found no association between the type or site of FH mutation and any aspect of the MCUL phenotype. Biochemical assay for reduced FH functional activity in the germline of MCUL patients can indicate carriers of FH mutations with high sensitivity and specificity, and can detect reduced FH activity in some patients without detectable FH mutations. We conclude that MCUL is probably a genetically homogeneous tumour predisposition syndrome, primarily resulting from absent or severely reduced fumarase activity, with currently unknown functional consequences for the smooth muscle or kidney cell.


Asunto(s)
Fumarato Hidratasa/genética , Neoplasias Renales/genética , Leiomiomatosis/genética , Mutación , Neoplasias Cutáneas/genética , Neoplasias Uterinas/genética , Errores Innatos del Metabolismo de los Aminoácidos/genética , Secuencia de Aminoácidos , Estabilidad de Enzimas , Femenino , Fumarato Hidratasa/química , Fumarato Hidratasa/deficiencia , Fumarato Hidratasa/metabolismo , Predisposición Genética a la Enfermedad , Mutación de Línea Germinal , Humanos , Neoplasias Renales/secundario , Leiomiomatosis/patología , Datos de Secuencia Molecular , Conformación Proteica , Estabilidad del ARN , ARN Mensajero/metabolismo , Homología de Secuencia de Aminoácido , Neoplasias Cutáneas/patología , Neoplasias Uterinas/patología
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda